Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
December 19, 2016
Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma
December 15, 2016
Novocure to Participate in 35th Annual J.P. Morgan Healthcare Conference
December 12, 2016
Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year Survival Rate of Patients with Advanced Pancreatic Cancer
December 12, 2016
Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer
December 8, 2016
Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
November 18, 2016
Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates
November 17, 2016
Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma
November 14, 2016
Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology
November 7, 2016
Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology
November 3, 2016
United Healthcare Issues Positive Coverage Decision for Optune
November 2, 2016
Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update
November 1, 2016
Novocure Recognizes National Family Caregivers Month by Supporting GBM Heroes Event
October 12, 2016
Novocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial
September 30, 2016
CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results
September 30, 2016
Novocure to Report Third Quarter 2016 Financial Results
September 19, 2016
CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma
September 15, 2016
Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine
September 14, 2016
Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields
September 12, 2016
Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Interim Analysis
September 1, 2016
International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo
August 16, 2016
Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13
August 8, 2016
Novocure to Present at Upcoming Investor Conferences
July 28, 2016
Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update
July 28, 2016
Novocure to Host Research and Development Day on Dec. 12, 2016
July 26, 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
July 13, 2016
Novocure Receives FDA Approval for Second Generation Optune System
June 30, 2016
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors
June 30, 2016
Novocure to Report Second Quarter 2016 Financial Results
June 8, 2016
Novocure to Present at JMP Securities 2016 Life Sciences Conference
May 31, 2016
Novocure Receives IDE Approval to Initiate METIS Trial
May 23, 2016
Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer
May 19, 2016
Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer
May 18, 2016
Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients
May 13, 2016
Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016
May 11, 2016
Novocure Enters into Employment Agreement with William Doyle
May 9, 2016
Novocure Reports First Quarter 2016 Financial Results and Provides Company Update
May 6, 2016
Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma
May 5, 2016
Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer
May 4, 2016
Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune
April 26, 2016
Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.
April 25, 2016
FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
April 15, 2016
OpportunityAnalyzer: Glioblastoma – Opportunity Analysis and Forecasts to 2024 – Research and Markets
April 7, 2016
Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016
April 5, 2016
Novocure to Report First Quarter 2016 Financial Results
March 31, 2016
Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields
March 9, 2016
Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma
March 3, 2016
Humana Issues Positive Coverage Decision For Optune
February 29, 2016
Novocure Reports 2015 Operating Statistics and Financial Results
February 23, 2016
Novocure to Present at Cowen and Company 36th Annual Health Care Conference
February 12, 2016
Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma
February 9, 2016
Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report
February 1, 2016
Novocure to Report Fourth Quarter, Year-End Financial Results
January 19, 2016
Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer
January 11, 2016
Novocure Announces Preliminary 2015 Operating Statistics
January 7, 2016
Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients
January 6, 2016
Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System
January 4, 2016
Novocure to Participate in 34th Annual J.P. Morgan Healthcare Conference